Biotechnology. Scored on the same transparent model behind the daily rankings.
★
PTCT
PTC Therapeutics, Inc. · Biotechnology
23.2Score
$64.70Oct 9 close$5.4B
1Y Target$101.07Analyst consensus · 14 analysts
5Y Target$176.77Compound horizon
10Y Target$315.93Long-dated conviction
FCF-$40mTTM · 06/26F
FCF is negative (-$40m) — cash-burning phase; acceptable only for pre-profit spec names · TTM from SEC filings (OCF − CapEx), four quarters to 06/26.
Rev-42.8%TTM YoYF
Revenue -42.8% — severe decline · Latest four quarters of revenue vs the four before them, from SEC filings.
D/ENegative equity—
Shareholders' equity is below zero, usually after years of share buybacks, so debt-to-equity has no meaning here. When the company earns an operating profit, the score measures its debt as net debt against that profit instead.
P/S*5.4xB
P/S 5.4x — near the Healthcare median (≈60th pctile)
PEG*——
PEG n/a — no positive earnings to base it on
* P/S replaces P/E — no positive earnings to divide by
* PEG n/a — no positive earnings to base it on
Targets: 1-year is analyst consensus where covered, 5- and 10-year are model estimates; the DCF is a cross-check, not a target. Methodology
Quality-growth score · 23.2
Quality59.8
Growth14.7
Value14.2
Why this score
Diluting shareholders
Entry · Margin of safety
52-week rangeNear 52-week low
29% off the 12-month high
Quality signals
Gross profitability31% · B+gross profit ÷ total assets — not in the score
ROIC23.3% · Areturn on invested capital — leads the quality score
Model-generatedFrom reported fundamentals, checked against the figures above · Editorial standards
Why now
Biotechnology · market cap $5.4b. Down 29% from 52-week high of $90.87 — deep drawdown territory. Revenue -43% — in contraction; any catalyst that reverses this triggers re-rating. 14 sell-side analysts rate this a Buy with a mean 1-yr target of $101.07 (implying +56% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$40m) — capital raises or debt issuance likely required; dilution / leverage risk. Revenue contracting -43% — the operational turn is not yet visible in the top line. Currently unprofitable (margin -3.8%) — path to GAAP profitability is the core thesis risk.
Horizon
1-3 yr $101.07 (14-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $176.77 — requires the platform / technology to reach commercial scale. 10 yr $315.93 — return distribution heavily skewed.
PTCT vs the Top Picks average
Pillar
PTCT
Book avg
Diff
Quality
60
83
-23
Growth
15
89
-74
Value
14
76
-62
Average of today's Top 30 (mean score 82.6); size and sector limits also decide the book.
Score history · PTCT
Trend
-16.0 over 82 daily scores
From 39.2 (Jun 22) → 23.2 (now)
One point per daily run; read From → To for the actual range.
PTCT at a glance
Same audited fundamentals as the score, unless a card says otherwise.
Analyst estimate revisions
30-day change
-5.2%
90-day change
-23.2%
Forward EPS estimate
$2.37
Over the last 90 days, what analysts expect PTCT to earn is materially lower (-23.2%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
Estimates move both ways and are not part of the Bull Rankings score. Biggest movers →
Position sizing · PTCT
$
%
%
Shares to buy
30
Position size
$1,941
3.9% of portfolio
Stop price
$48.53
25% below $64.70
$ at risk if stopped
$485.25
budget $500.00 · 1% of portfolio
Math only: excludes commissions, slippage and gap risk. Inputs stay in your browser.
PTC Therapeutics, Inc. (PTCT): score, valuation & FAQ
PTC Therapeutics, Inc. (PTCT) is a Biotechnology company that scores 23.2 out of 100 on the Bull Rankings quality-growth model — a weak reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
The model flags FCF (F) and Rev (F) as weaker areas.
Is PTCT a good stock to buy?
Bull Rankings scores PTCT 23.2 out of 100 on its quality-growth model, which is a weak reading. A score is a quantitative screen of PTC Therapeutics, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does PTCT score 23.2 on Bull Rankings?
The score leans on quality at 59.8 out of 100, with value the weakest pillar at 14.2 — the three combine geometrically, so a weak one cannot be papered over by a strong one. PTCT grades middle-of-pack across the graded signals, and is held back by FCF (F) and Rev (F). Each signal is graded against sector-aware thresholds rather than one absolute bar, so PTCT is measured against Biotechnology peers, not against the market as a whole.
Is PTCT overvalued or undervalued?
We don't compute a reliable discounted-cash-flow value for PTCT — typically because it is not yet consistently profitable or free-cash-flow positive — so its valuation rests on growth and price-to-sales rather than on earnings-based intrinsic value. Judge it on the trajectory of the business, not a single multiple.
What are the main risks of investing in PTCT?
Free cash flow is negative (-$40m) — capital raises or debt issuance likely required; dilution / leverage risk. Revenue contracting -43% — the operational turn is not yet visible in the top line. Currently unprofitable (margin -3.8%) — path to GAAP profitability is the core thesis risk.